Kyu-Tae Kim
Overview
Explore the profile of Kyu-Tae Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Oh B, Shin H, Yun J, Kim K, Kim J, Bae J, et al.
Sci Rep
. 2019 Mar;
9(1):4542.
PMID: 30872730
Tumor genetic heterogeneity may underlie poor clinical outcomes because diverse subclones could be comprised of metastatic and drug resistant cells. Targeted deep sequencing has been used widely as a diagnostic...
12.
Shin S, Park S, Ju E, Park J, Ko E, Hwang J, et al.
Anticancer Res
. 2017 Dec;
38(1):287-293.
PMID: 29277785
Background/aim: To maximize success rate for development of HER2-targeted therapeutics, patient-derived xenograft (PDX) models reflecting HER2-positive gastric cancer (HER2 GC) patients were established. Materials And Methods: GC tissues obtained from...
13.
Han K, Kim K, Joung J, Son D, Kim Y, Jo A, et al.
Genome Res
. 2017 Dec;
28(1):75-87.
PMID: 29208629
Simultaneous sequencing of the genome and transcriptome at the single-cell level is a powerful tool for characterizing genomic and transcriptomic variation and revealing correlative relationships. However, it remains technically challenging...
14.
Kim S, Kim K, Kim N, Park J, Ahn S, Yun J, et al.
Oncologist
. 2017 Jul;
22(10):1169-1177.
PMID: 28701572
Implications For Practice: This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding...
15.
Chung W, Eum H, Lee H, Lee K, Lee H, Kim K, et al.
Nat Commun
. 2017 May;
8:15081.
PMID: 28474673
Single-cell transcriptome profiling of tumour tissue isolates allows the characterization of heterogeneous tumour cells along with neighbouring stromal and immune cells. Here we adopt this powerful approach to breast cancer...
16.
Frejd F, Kim K
Exp Mol Med
. 2017 Mar;
49(3):e306.
PMID: 28336959
Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class...
17.
Lee J, Wang J, Sa J, Ladewig E, Lee H, Lee I, et al.
Nat Genet
. 2017 Mar;
49(4):594-599.
PMID: 28263318
Precision medicine in cancer proposes that genomic characterization of tumors can inform personalized targeted therapies. However, this proposition is complicated by spatial and temporal heterogeneity. Here we study genomic and...
18.
Um S, Joung J, Lee H, Kim H, Kim K, Park J, et al.
Cancer Res
. 2016 Sep;
76(22):6568-6576.
PMID: 27634761
Tumor heterogeneity influences the clinical outcome of patients with cancer, and the diagnostic method to measure the tumor heterogeneity needs to be developed. We analyzed genomic features on pairs of...
19.
Kim K, Lee H, Lee H, Song H, Jeong D, Shin S, et al.
Genome Biol
. 2016 May;
17:80.
PMID: 27139883
Background: Intratumoral heterogeneity hampers the success of marker-based anticancer treatment because the targeted therapy may eliminate a specific subpopulation of tumor cells while leaving others unharmed. Accordingly, a rational strategy...
20.
Ryu D, Joung J, Kim N, Kim K, Park W
Hum Genet
. 2016 Apr;
135(6):635-42.
PMID: 27126234
Intratumor heterogeneity within individual cancer tissues underlies the numerous phenotypes of cancer. Tumor subclones ultimately affect therapeutic outcomes due to their distinct molecular features. Drug-resistant subclones are present at a...